Benzinga | Jun 22, 2021 07:11AM EDT

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $250

Barclays analyst Balaji Prasad maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $235 to $250.